Aura Biosciences director granted RSUs, options

Aura Biosciences director Antony C. Mattessich received new equity awards.

Rhea-AI Filing Summary

Aura Biosciences director Antony C. Mattessich received new equity awards. On June 11, 2026, he was granted 15,000 shares of Common Stock through a restricted stock unit award and now holds 38,500 Common Stock shares directly.

The RSUs were granted under the 2021 Stock Option and Incentive Plan, with each RSU representing one share of Common Stock. They vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to his continued service.

He was also granted stock options covering 30,000 shares of Common Stock at an exercise price of $6.21 per share. These options vest and become exercisable on the same earlier-of vesting schedule and expire on June 11, 2036.

Insider Trade Summary

Grant/Award: 45,000 shares

Grant/Award 2 txns

Insider Mattessich Antony C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	$0.00
Grant/Award	Common Stock	15,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 contracts (Direct); Common Stock — 38,500 shares (Direct)

Footnotes (2)

1. F1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.
2. F2. This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

Key Figures

RSU grant: 15,000 shares Common stock holdings: 38,500 shares Stock options granted: 30,000 options +3 more

6 metrics

RSU grant 15,000 shares Restricted stock units granted June 11, 2026

Common stock holdings 38,500 shares Shares directly held after RSU grant

Stock options granted 30,000 options Options on Common Stock granted June 11, 2026

Option exercise price $6.21 per share Conversion or exercise price for new options

Option expiration June 11, 2036 Expiration date of stock options

RSU vesting date June 11, 2027 Latest date; or earlier at next annual meeting

Key Terms

restricted stock unit ("RSU") award, 2021 Stock Option and Incentive Plan, Stock Option (Right to Buy), vest in full, +1 more

5 terms

restricted stock unit ("RSU") award financial

"These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan."

2021 Stock Option and Incentive Plan financial

"These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan."

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest in full financial

"These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders"

exercise price financial

"conversion_or_exercise_price": "6.2100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Aura Biosciences (AURA) grant to Antony C. Mattessich?

Aura Biosciences granted director Antony C. Mattessich 15,000 restricted stock units and stock options for 30,000 shares. The RSUs and options were issued under the 2021 Stock Option and Incentive Plan as compensation, not open-market purchases or sales.

When do Antony C. Mattessich’s new Aura Biosciences RSUs vest?

The 15,000 RSUs granted to Antony C. Mattessich vest in full on the earlier of June 11, 2027 or the next Aura Biosciences annual stockholder meeting. Vesting is conditioned on his continued service through the applicable vesting date.

What are the key terms of the new Aura Biosciences stock options?

Mattessich received options for 30,000 Aura Biosciences shares at an exercise price of $6.21 per share. These options vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting and expire on June 11, 2036.

How many Aura Biosciences shares does Antony C. Mattessich hold after this Form 4?

Following the RSU grant, Antony C. Mattessich directly holds 38,500 shares of Aura Biosciences Common Stock. He also holds stock options covering 30,000 additional shares, which become exercisable when the vesting conditions are satisfied.

Is Antony C. Mattessich’s Form 4 transaction a market buy or sell of AURA stock?

The Form 4 reports compensation-related grants, not market trades. Mattessich acquired 15,000 RSUs and options for 30,000 shares as awards, both at a reported price of $0.00 per share, subject to vesting and, for options, future exercise at $6.21.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mattessich Antony C.

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		15,000(1)	A	$0	38,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.21	06/11/2026		A		30,000		(2)	06/11/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

2. This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

	/s/ Conor Kilroy, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)